G1 Therapeutics, Inc. financial data

Location
Research Triangle Park, NC
Fiscal year end
31 December
Latest financial report
10-Q - Q2 2024 - 08 Aug 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 322% % -28%
Quick Ratio 39% % -11%
Debt-to-equity 248% % 21%
Return On Equity -137% % 4.4%
Return On Assets -39% % 16%
Operating Margin -65% % 13%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 52,758,191 shares 2%
Common Stock, Shares, Outstanding 52,697,879 shares 1.9%
Weighted Average Number of Shares Outstanding, Basic 52,475,190 shares 1.6%
Weighted Average Number of Shares Outstanding, Diluted 52,475,190 shares -14%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $58,195,000 USD -35%
Research and Development Expense $29,247,000 USD -54%
Operating Income (Loss) $37,880,000 USD 43%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $42,963,000 USD 43%
Income Tax Expense (Benefit) $1,807,000 USD -40%
Net Income (Loss) Attributable to Parent $44,770,000 USD 42%
Earnings Per Share, Basic -1 USD/shares 48%
Earnings Per Share, Diluted -1 USD/shares 51%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $15,074,000 USD -73%
Marketable Securities, Current $45,656,000 USD -5.5%
Accounts Receivable, after Allowance for Credit Loss, Current $13,309,000 USD 1%
Inventory, Net $13,383,000 USD -14%
Assets, Current $92,922,000 USD -34%
Property, Plant and Equipment, Net $1,235,000 USD -28%
Operating Lease, Right-of-Use Asset $4,345,000 USD -20%
Assets $98,689,000 USD -33%
Accounts Payable, Current $5,156,000 USD -11%
Employee-related Liabilities, Current $1,972,000 USD -28%
Accrued Liabilities, Current $17,081,000 USD -31%
Liabilities, Current $37,504,000 USD 11%
Operating Lease, Liability, Noncurrent $3,646,000 USD -27%
Other Liabilities, Noncurrent $41,000 USD
Liabilities $74,097,000 USD -18%
Retained Earnings (Accumulated Deficit) $795,673,000 USD -6%
Stockholders' Equity Attributable to Parent $24,592,000 USD -57%
Liabilities and Equity $98,689,000 USD -33%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $8,898,000 USD 69%
Net Cash Provided by (Used in) Financing Activities $8,722,000 USD -3976%
Net Cash Provided by (Used in) Investing Activities $5,289,000 USD 82%
Common Stock, Shares Authorized 120,000,000 shares 0%
Common Stock, Shares, Issued 52,724,545 shares 1.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $12,331,000 USD 53%
Interest Paid, Excluding Capitalized Interest, Operating Activities $1,823,000 USD -27%
Depreciation $881,000 USD 64%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $120,000 USD -9.1%
Share-based Payment Arrangement, Expense $11,500,000 USD -32%